OXGN - avanço tecnologico na cura do cancro...
Enviado: 23/8/2005 21:42Oxigene (OXGN:Nasdaq - commentary - research - Cramer's Take) rose 10% after the company presented positive data showing that its lead vascular disruption agent, Combretastatin A4 Prodrug, is doing well in combination trials with chemotherapy. The drug, in combination with carboplatin and paclitaxel, appears to be well tolerated and no drug-related, serious adverse events have occurred, the company said.
The data, which were presented by Dr. Gordon Rustin at the Ninth International Workshop on the Tumor Microenvironment Meeting being held in the U.K., "are encouraging from both a safety and an anti-tumor response perspective," the company said. Tumor response, as defined according to RECIST or CA125, has been seen in seven out of 12 evaluable patients with ovarian cancer, the company said
The data, which were presented by Dr. Gordon Rustin at the Ninth International Workshop on the Tumor Microenvironment Meeting being held in the U.K., "are encouraging from both a safety and an anti-tumor response perspective," the company said. Tumor response, as defined according to RECIST or CA125, has been seen in seven out of 12 evaluable patients with ovarian cancer, the company said